Eli Lilly has posted a net income of $1.349bn for the second quarter 2010, or $1.22 per diluted share, compared to $1.159bn, or $1.06 per diluted share, for the comparable period in 2009. Operating income was $1.755bn, compared to $1.492bn, an increased 18% for the comparable period in 2009.
For the six months ended June 30, 2010, Eli Lilly has posted a net income of $2.597bn, or $2.35 per diluted share, compared to $2,472bn, or $2.25 per diluted share, for the year ago period.
Eli Lilly has reported for the first six months of 2010, worldwide total revenue increased 9% to $11.234bn, compared with the same period in 2009.
John Lechleiter, chairman and CEO of Lilly, said: “Lilly continued to deliver solid financial results in the second quarter, driven by volume-based revenue gains and ongoing cost-containment efforts that resulted in double-digit earnings growth.
“We’re pleased with these results and the opportunities they create. This strong financial performance enables us to fund our R&D pipeline of nearly 70 clinical stage assets and make strategic acquisitions in order to deliver an increased number of innovative medicines to patients in the future.”